Acta dermato-venereologica最新文献_第5页

Treatment Patterns, Healthcare Utilization, and Related Costs for Prurigo Nodularis in Sweden. 瑞典结节性痒疹的治疗模式、医疗保健利用和相关费用

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-08-18 DOI: 10.2340/actadv.v105.43730

Laura Von Kobyletzki, Alexandra Metsini, Simon E Regnell, Michael Carlberg, Åke Svensson, Annarita Antelmi

{"title":"Treatment Patterns, Healthcare Utilization, and Related Costs for Prurigo Nodularis in Sweden.","authors":"Laura Von Kobyletzki, Alexandra Metsini, Simon E Regnell, Michael Carlberg, Åke Svensson, Annarita Antelmi","doi":"10.2340/actadv.v105.43730","DOIUrl":"10.2340/actadv.v105.43730","url":null,"abstract":"Prurigo nodularis (PN) is a chronic, itchy, inflammatory skin condition that negatively affects quality of life. A study was undertaken to investigate the healthcare utilization, including treatment patterns and direct costs for specialist care, for PN in Sweden. Linkage cohorts were created from national Swedish patient and prescription registers, and the cost-per-patient database of PN adults in specialist care in Sweden from 2015 to 2020. Around 875 patients were registered annually with a specialist diagnosis of PN in Sweden, with 3,548 specialist visits per year on average. In patients with severe PN with AD, the most common treatment sequence was topical treatment with corticosteroids followed by systemic prednisolone and methotrexate (32.6%). More than one-fifth of individuals with PN, and most with severe PN, had treatment for more than 1 year. For in- and outpatient care, the mean cost per visit was €458.6 and per patient per year around €1,862. The total annual cost of PN patients is estimated to be €1.6 million in Sweden. A high proportion of patients are treated for years with several, often systemic, treatment sequels. Targeted treatments for PN might improve patients' quality of life and reduce the high related costs for the healthcare system.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43730"},"PeriodicalIF":3.7,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144870733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IgA Vasculitis Induced by Ustekinumab During Treatment for Crohn's Disease: A Case Report. 克罗恩病治疗期间Ustekinumab诱导IgA血管炎1例报告

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-08-13 DOI: 10.2340/actadv.v105.44276

Yu Okada, Yuko Ehara, Kazuo Yashima, Yuichi Yoshida

引用次数: 0

Unanticipated Squamous Cell Carcinoma in a Giant Verrucous Venous Malformation. 巨大疣状静脉畸形的意外鳞状细胞癌。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-08-13 DOI: 10.2340/actadv.v105.44208

Jie Tao, Bin Sun, Shih-Jen Chang, Xiaoxi Lin, Yajing Qiu

引用次数: 0

Topical Steroid Withdrawal: Perspectives of Dutch Healthcare Professionals. 局部类固醇戒断：荷兰医疗保健专业人员的观点。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-08-12 DOI: 10.2340/actadv.v105.44209

Florence Vroman, Charlotte S Schimmel, Lisa P Van der Rijst, Marlies De Graaf, Marjolein De Bruin-Weller, Patrick M J H Kemperman, Dirk Jan Hijnen, Inge M Haeck

{"title":"Topical Steroid Withdrawal: Perspectives of Dutch Healthcare Professionals.","authors":"Florence Vroman, Charlotte S Schimmel, Lisa P Van der Rijst, Marlies De Graaf, Marjolein De Bruin-Weller, Patrick M J H Kemperman, Dirk Jan Hijnen, Inge M Haeck","doi":"10.2340/actadv.v105.44209","DOIUrl":"10.2340/actadv.v105.44209","url":null,"abstract":"Topical steroid withdrawal (TSW) is a highly controversial condition, typically reported following prolonged and/or frequent use of topical corticosteroids. Despite growing public awareness, knowledge of topical steroid withdrawal remains limited. Therefore, this study aimed to explore the perspectives of Dutch healthcare professionals (HCPs) on topical steroid withdrawal. A web-based survey was conducted among 168 Dutch HCPs. The results show that erythema (64.1%) and a burning sensation (60.3%) were the most frequently selected symptoms associated with TSW. The majority of respondents (69.6%) attributed TSW symptoms to atopic dermatitis (AD) flares and/or the adverse effect of topical corticosteroid use. Only a small percentage (12.2%) firmly believed that TSW is a distinct clinical entity, while 17.6% believed that it does not exist. Preferred treatments included using other topical immunomodulators, reinitiating and subsequently tapering topical corticosteroids, and providing non-drug and psychological support. While HCPs felt confident in addressing concerns about topical corticosteroids and topical steroid withdrawal, approximately one-quarter (24.2%) preferred not to treat patients refusing topical corticosteroids. This study highlights variations in perception among HCPs and the need for robust research to establish clear diagnostic criteria and guidelines regarding TSW. Finally, improved awareness and open communication between HCPs and patients are essential when addressing topical steroid withdrawal.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv44209"},"PeriodicalIF":3.7,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12359819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies for Managing Suboptimal Response to JAK Inhibitors in Alopecia Areata. 斑秃患者对JAK抑制剂反应欠佳的管理策略。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-08-12 DOI: 10.2340/actadv.v105.44193

S Morteza Seyed Jafari, Pierre A De Viragh

引用次数: 0

Familial Amyloidosis Cutis Dyschromica with GPNMB mutation: A Case Report and Literature Review. 家族性皮肤淀粉样变性伴GPNMB突变1例并文献复习。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-08-12 DOI: 10.2340/actadv.v105.43888

Suvijak Untaaveesup, Tanaporn Borriboon, Chavalit Supsrisunjai

引用次数: 0

Erythematous Follicular Papules on the Thighs: A Quiz. 大腿上的红斑性毛囊丘疹：一个小测验。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-08-11 DOI: 10.2340/actadv.v105.44139

Shin Iinuma, Takahiro Kobayashi, Akemi Ishida-Yamamoto, Yasuyuki Fujita

引用次数: 0

Oesophageal Lichen Planus: Case Series and Review of the Literature. 食道扁平苔藓：病例系列及文献回顾。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-08-11 DOI: 10.2340/actadv.v105.43358

Nerea Manzanares, Andrea Molina-Alvarez, Mar Iglesias, Juan Enrique Naves, Ramon M Pujol, Sonia Segura

{"title":"Oesophageal Lichen Planus: Case Series and Review of the Literature.","authors":"Nerea Manzanares, Andrea Molina-Alvarez, Mar Iglesias, Juan Enrique Naves, Ramon M Pujol, Sonia Segura","doi":"10.2340/actadv.v105.43358","DOIUrl":"10.2340/actadv.v105.43358","url":null,"abstract":"Lichen planus affects 0.5% to 2% of the population. The involvement of the oesophagus is a rare manifestation with high morbidity and risk of malignancy. Clinical characteristics and diagnostic-therapeutic strategies were reviewed. A retrospective study of clinical-pathological characteristics, endoscopic findings, and follow-up of patients with oesophageal lichen planus treated at a tertiary hospital during 2006-2023 was conducted. Nine patients (1 man, 8 women) with a median age of 76 years were included. All patients had oral lichen planus. Dysphagia was the initial symptom, being the first manifestation of the disease in 2 cases. All presented lesions in the oral oesophagus with fibrous rings, stenosis, and mucosal denudation. Histological changes of the lichenoid type were observed in 8/9. After a median follow-up of 2 years, no progression to oesophageal squamous cell carcinoma was observed. Swallowed glucocorticoid therapy, proton pump inhibitors, prokinetics, and oesophageal dilatations were prescribed. Eight out of 9 patients showed partial improvement with clinical stabilization. Oesophageal lichen planus is an infrequent and underdiagnosed disease. Its diagnosis may be based on endoscopic features, histopathology, and direct immunofluorescence. The correct management is often challenging, but necessary because this entity has been associated with oesophageal squamous cell carcinoma.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43358"},"PeriodicalIF":3.7,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12359818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144815541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish Cohort. 特应性皮炎的药物生存期和全身治疗结果的预测因素：来自瑞典全国队列的数据。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-08-07 DOI: 10.2340/actadv.v105.43464

Pontus O Jonsson, Mahsa Tayefi, Axel Svedbom, Maria Bradley, Emma K Johansson

{"title":"Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish Cohort.","authors":"Pontus O Jonsson, Mahsa Tayefi, Axel Svedbom, Maria Bradley, Emma K Johansson","doi":"10.2340/actadv.v105.43464","DOIUrl":"10.2340/actadv.v105.43464","url":null,"abstract":"Real-world data on the drug survival of established and emerging treatment options in atopic dermatitis provide a comprehensive measure of the efficacy and tolerability of these interventions, which may enable improvements in clinical management. This study aimed to describe the drug survival, with associated predictors, of treatment with abrocitinib, baricitinib, cyclosporine, dupilumab, methotrexate, tralokinumab, and upadacitinib among patients with atopic dermatitis in Sweden who were recruited into the multicentre prospective SwedAD cohort between January 2017 and April 2024. A total of 1,194 patients were included with a total of 1,486 treatment episodes. The 2-year drug survival probability was 14.2% for baricitinib (treatment episodes, n = 30), 12.2% for cyclosporine (n = 40), 79.7% for dupilumab (n = 1,026), 45.4% for methotrexate (n = 260), and 46.0% for upadacitinib (n = 89). Two-year follow-up data were not available for abrocitinib (n = 23) or tralokinumab (n = 18). All drugs were compared with the most used conventional systemic treatment at study baseline, methotrexate, using Cox regression. Only dupilumab showed a significantly lower hazard rate of drug discontinuation. In conclusion, dupilumab therapy demonstrated longer drug survival than methotrexate in atopic dermatitis. The impact of national treatment guidelines and time since drug approval should be considered when interpreting the results.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43464"},"PeriodicalIF":3.7,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is TRIM11 Immunohistochemical Positivity Specific for the Diagnosis of CRTC1::TRIM11 Cutaneous Tumors? TRIM11免疫组化阳性诊断CRTC1::TRIM11皮肤肿瘤特异性吗？

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-08-07 DOI: 10.2340/actadv.v105.44357

Shangshen Chen, Yeqiang Liu, Mingyuan Xu, Wei Tan

引用次数: 0